GlassScriptPhysician profile
James C Campau
NPI 1932147758
$32,354.32
in general payments reported to CMS, 2019-2025
61 companies · $3,028 in 2025
The $3,028 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,236 · 2020: $9,802 · 2021: $5,866 · 2022: $4,032 · 2023: $3,260 · 2024: $3,131 · 2025: $3,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,412 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,411.94 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15,018.56 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $2,320.08 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Lilly USA, LLC | $1,900.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,653.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,273.90 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $966.23 | 2019-2024 | Spravato |
| Amgen INC. | $932.14 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $739.79 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $592.01 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $561.69 | 2019-2023 | |
| Dexcom, INC. | $458.43 | 2019-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $449.46 | 2019-2024 | Trintellix |
| Astellas Pharma US INC | $423.50 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $417.14 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $388.53 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Campau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.